Market Overview

Human milk oligosaccharides (HMOs), which are tiny sugar molecules, may be found in substantial concentrations in breast milk. After lipids and carbohydrates, these nutrients are the third most common component of mother's milk. The global market for human milk oligosaccharides is growing because of the increased use of human milk oligosaccharides in food supplements and the increased availability of new-born formula. The high cost of manufacture, on the other hand, is limiting the growth of the global market for human milk oligosaccharides.

Over the last few years, growing health awareness has resulted in substantial changes in behaviour and nutrition, increasing the supply of food supplements such as nutritional supplements and probiotics around the world. Because of its benefits, including boosting gut flora and strengthening the defence system, growing data supports the use of HMOs in adult nutrition products such as functional meals and supplements. HMOs have been found to reduce the number of hazardous germs like salmonella and campylobacter in beverages and snacks, in addition to supporting the development of good microorganisms in functional foods and drinks. These factors are expected to contribute to the Human Milk Oligosaccharides Market's expansion throughout the forecast period.

Human Milk Oligosaccharides Market Size is anticipated to reach USD 332.4 million by 2030, registering a CAGR of 14.4% during 2022-2030

Market segmentation

Based on the Application, the global Human Milk Oligosaccharides Market has been segmented into the food industry and laboratory research.

Based on the end-users, the global Human Milk Oligosaccharides Market has been segmented into neutral and acidic.

Based on the region, the global Human Milk Oligosaccharides Market has been segmented into North America, Europe, Asia-Pacific, and the Rest of the World.

Regional Classification

North America represented the largest share of the global human milk oligosaccharides market during the historic forecast period, owing to the clear increased consumption of infant food in the region. The European market for human milk oligosaccharides became the second-highest revenue share of the global economy for the first time.

According to UNICEF research, the United Kingdom has one of the lowest rates of breastfeeding in the world, with only 34% of newborns receiving breast milk by the age of six months. As a result, the most crucial variables influencing the expansion of the European marketplace are decreased breastfeeding prices and an increasing number of EU certifications for newly introduced HMO-based medicines. Because of the decline in the number of newborns, Japan had the smallest share of the global human milk oligosaccharides market. The Japanese market accounted for 3.26 percent of the global Human Milk Oligosaccharides Market.

Major Players

The major key Human Milk Oligosaccharides Market players are Abbott (US), Dextra Laboratories Limited (UK), BASF SE (Germany), DuPont Nutrition Health (Denmark), Glycom (Denmark), Elicityl S.A. (France), Jennewein Biotechnologie GmbH (Germany), Glycosyn LLC (US), Inbiose NV (Belgium), Medolac Laboratories (US), ZuChem (US), and Nestle Health Science (Switzerland).

Industry Updates:

Aug 2020 Conagen, a Boston-based biotechnology company, has shown a novel and proprietary procedure for the scalable manufacture of a non-GMO human milk oligosaccharide (HMO), a vital nutritional compound only seen in human milk. This micronutrition innovation will permit the conception of high-quality and lucrative next-generation infant formula products that are like human breast milk.

NOTE: Our Team of Researchers are Studying Covid19 and its Impact on Various Industry Verticals and wherever required we will be considering Covid19 Footprints for Better Analysis of Market and Industries. Cordially get in Touch for More Details.

Contact Us:

Market Research Future®

99 Hudson Street, 5Th Floor

New York, New York 10013

United States of America

Email: sales@marketresearchfuture.com